» Articles » PMID: 15241791

CASRdb: Calcium-sensing Receptor Locus-specific Database for Mutations Causing Familial (benign) Hypocalciuric Hypercalcemia, Neonatal Severe Hyperparathyroidism, and Autosomal Dominant Hypocalcemia

Overview
Journal Hum Mutat
Specialty Genetics
Date 2004 Jul 9
PMID 15241791
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Familial hypocalciuric hypercalcemia (FHH) is caused by heterozygous loss-of-function mutations in the calcium-sensing receptor (CASR), in which the lifelong hypercalcemia is generally asymptomatic. Homozygous loss-of-function CASR mutations manifest as neonatal severe hyperparathyroidism (NSHPT), a rare disorder characterized by extreme hypercalcemia and the bony changes of hyperparathyroidism, which occur in infancy. Activating mutations in the CASR gene have been identified in several families with autosomal dominant hypocalcemia (ADH), autosomal dominant hypoparathyroidism, or hypocalcemic hypercalciuria. Individuals with ADH may have mild hypocalcemia and relatively few symptoms. However, in some cases seizures can occur, especially in younger patients, and these often happen during febrile episodes due to intercurrent infection. Thus far, 112 naturally-occurring mutations in the human CASR gene have been reported, of which 80 are unique and 32 are recurrent. To better understand the mutations causing defects in the CASR gene and to define specific regions relevant for ligand-receptor interaction and other receptor functions, the data on mutations were collected and the information was centralized in the CASRdb (www.casrdb.mcgill.ca), which is easily and quickly accessible by search engines for retrieval of specific information. The information can be searched by mutation, genotype-phenotype, clinical data, in vitro analyses, and authors of publications describing the mutations. CASRdb is regularly updated for new mutations and it also provides a mutation submission form to ensure up-to-date information. The home page of this database provides links to different web pages that are relevant to the CASR, as well as disease clinical pages, sequence of the CASR gene exons, and position of mutations in the CASR. The CASRdb will help researchers to better understand and analyze the mutations, and aid in structure-function analyses.

Citing Articles

Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations.

De Coster T, David K, Breckpot J, Decallonne B J Endocrinol Invest. 2024; .

PMID: 39607645 DOI: 10.1007/s40618-024-02496-y.


Molecular dynamics study of tropical calcific pancreatitis (TCP) associated calcium-sensing receptor single nucleotide variation.

Shrivastava A, Mathur K, Verma R, Magani S, Vyas D, Singh A Front Mol Biosci. 2022; 9:982831.

PMID: 36275616 PMC: 9581290. DOI: 10.3389/fmolb.2022.982831.


Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer.

Beasley H, Widatalla S, Whalen D, Williams S, Korolkova O, Namba C Front Endocrinol (Lausanne). 2022; 13:816598.

PMID: 35355564 PMC: 8959981. DOI: 10.3389/fendo.2022.816598.


Novel mutations of the calcium-sensing receptor impede differential diagnosis of primary hyperparathyroidism and familial hypocalciuric hypercalcemia.

Bhangu J, Baumgartner-Parzer S, Hargitai L, Mazal P, Scheuba C, Riss P Gland Surg. 2022; 11(1):12-22.

PMID: 35242665 PMC: 8825529. DOI: 10.21037/gs-21-577.


Calcium-Sensing Receptor Polymorphisms at rs1801725 Are Associated with Increased Risk of Secondary Malignancies.

Actkins K, Beasley H, Faucon A, Davis L, Sakwe A J Pers Med. 2021; 11(7).

PMID: 34357109 PMC: 8304025. DOI: 10.3390/jpm11070642.